Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature

Maxime Quaggetto; Thouraya Ben salem; Julien Haroche; Julien Campagne; Quentin Moyon; Raphael Lhote; Zahir Amoura; Fleur Cohen Aubart

doi:10.36141/svdld.v42i4.17246

Authors

Maxime Quaggetto Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares et Histiocytoses, Hôpital La Pitié-Salpêtrière, Paris, France https://orcid.org/0009-0004-9512-597X
Thouraya Ben salem Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares et Histiocytoses, Hôpital La Pitié-Salpêtrière, Paris, France https://orcid.org/0000-0002-5930-0038
Julien Haroche Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares et Histiocytoses, Hôpital La Pitié-Salpêtrière, Paris, France https://orcid.org/0009-0003-9794-1316
Julien Campagne Service de Médecine Interne, Hôpitaux UNEOS, Metz, France https://orcid.org/0000-0002-6186-4334
Quentin Moyon Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares et Histiocytoses, Hôpital La Pitié-Salpêtrière, Paris, France https://orcid.org/0000-0002-0223-5191
Raphael Lhote Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares et Histiocytoses, Hôpital La Pitié-Salpêtrière, Paris, France https://orcid.org/0000-0002-2729-4606
Zahir Amoura Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares et Histiocytoses, Hôpital La Pitié-Salpêtrière, Paris, France https://orcid.org/0000-0003-0292-9043
Fleur Cohen Aubart Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares et Histiocytoses, Hôpital La Pitié-Salpêtrière, Paris, France https://orcid.org/0000-0002-7610-4995

Keywords:

sarcoidosis, janus kinase, review

Abstract

Background and aim: Sarcoidosis is an inflammatory granulomatous disease of unknown cause affecting the lungs and frequently extra-thoracic organs. Several immunosuppressive agents have been evaluated in patients refractory to steroids or as steroids-sparing treatments with low level of evidence and conflicting results. JAK inhibitors (JAKi) are novel immunosuppressive agents and recent reports suggested their potential to induce disease response. We report four new sarcoidosis cases treated with JAKi and present a systematic review of the literature. Methods: We describe four new cases and conducted a literature review using Pubmed, Medline, Embase and Cochrane Library. All English-language reports of sarcoidosis patients treated with JAKi published between January 2004 and 2024 were included. Results: We included 4 cases, as well as 45 cases from a systematic review of the literature, reported in 21 articles, leading to a cohort of 49 patients (female 53%, median [IQR 25-75] age 55 [43-60] years). Most cases had pulmonary and cutaneous sarcoidosis, while cardiac and neurological sarcoidosis were less frequent. Indication for JAKi were: steroid sparing agent (29%), refractory disease (22%), non-sarcoidosis indication (10%) and not specified (39%). Most patients received Tofacitinib 5 mg twice daily. Median corticosteroids dosage at treatment initiation was 15 [10-25] mg/day. After a median follow-up of 8 [6-12] months, complete response was achieved in 45% of cases and partial response in 49%, with few adverse events reported.

Corticosteroids were discontinued in 11/23 (48%) and reduced in 6/23 (26%). Conclusions: JAK inhibitors appear to be a promising therapeutic option in sarcoidosis patients who are corticosteroid-dependent or refractory to conventional immunosuppressants. Prospective studies are now needed to confirm their efficacy and long-term safety.

References

1. Valeyre D, Bernaudin JF, Jeny F, et al. Pulmonary Sarcoidosis. Clinics in Chest Medicine. 2015 Dec;36(4):631–641. doi: 10.1016/j.ccm.2015.08.006.

2. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. The Lancet. 2014 Mar;383(9923):1155–1167. doi: 10.1016/S0140-6736(13)60680-7.

3. Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020 Mar 31;29(155):190146. doi: 10.1183/16000617.0146-2019.

4. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021 Dec;58(6):2004079. doi: 10.1183/13993003.04079-2020.

5. Kahlmann V, Janssen Bonás M, Moor CC, et al. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. N Engl J Med. 2025 May 18; doi: 10.1056/NEJMoa2501443.

6. Judson MA. Causes of Poor Medication Adherence in Sarcoidosis. Chest. 2020 July;158(1):17–18. doi: 10.1016/j.chest.2020.03.001.

7. Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respiratory Medicine. 2017 Nov;132:9–14. doi: 10.1016/j.rmed.2017.09.003.

8. Baughman RP, Drent M, Kavuru M, et al. Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement. Am J Respir Crit Care Med. 2006 Oct 1;174(7):795–802. doi: 10.1164/rccm.200603-402OC.

9. Vorselaars ADM, Verwoerd A, van Moorsel CHM, Keijsers RGM, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. European Respiratory Journal. 2014 Feb 1;43(2):602–609. doi: 10.1183/09031936.00055213.

10. Cohen Aubart F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017 May;264(5):891–897. doi: 10.1007/s00415-017-8444-9.

11. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. European Respiratory Journal. 2008 Mar 5;31(6):1189–1196. doi: 10.1183/09031936.00051907.

12. Doty JD, Mazur JE, Judson MA. Treatment of Corticosteroid-Resistant Neurosarcoidosis With a Short-Course Cyclophosphamide Regimen. Chest. 2003 Nov;124(5):2023–2026. doi: 10.1378/chest.124.5.2023.

13. Baughman R, Lower, Kaufman. Rituximab for refractory granulomatous eye disease. OPTH. 2012 Oct;1613. doi: 10.2147/OPTH.S35521.

14. Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. European Respiratory Journal. 2014 May 1;43(5):1525–1528. doi: 10.1183/09031936.00224513.

15. Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014 Nov;44(5):1296–1307. doi: 10.1183/09031936.00000914.

16. Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i43–i54. doi: 10.1093/rheumatology/key276.

17. Rosenbaum JT, Pasadhika S, Crouser ED, et al. Hypothesis: Sarcoidosis is a STAT1-mediated disease. Clinical Immunology. 2009 Aug;132(2):174–183. doi: 10.1016/j.clim.2009.04.010.

18. Celada LJ, Kropski JA, Herazo-Maya JD, et al. PD-1 up-regulation on CD4 + T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci Transl Med. 2018 Sept 26;10(460):eaar8356. doi: 10.1126/scitranslmed.aar8356.

19. Damsky W, Wang A, Kim DJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. 2022 June 6;13(1):3140. doi: 10.1038/s41467-022-30615-x.

20. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26–e51. doi: 10.1164/rccm.202002-0251ST.

21. Kozera E, Flora A, Frew JW. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study. J Am Acad Dermatol. 2022 Dec;87(6):1440–1442. doi: 10.1016/j.jaad.2022.07.047.

22. Savage KT, Santillan MR, Flood KS, Charrow A, Porter ML, Kimball AB. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep. 2020 Feb;6(2):99–102. doi: 10.1016/j.jdcr.2019.10.010.

23. Rotenberg C, Besnard V, Brillet PY, Giraudier S, Nunes H, Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018 Dec;52(6):1801482. doi: 10.1183/13993003.01482-2018.

24. Liu B, Yin H, Yang S, Lu L. Janus kinase inhibitor treatment improved both subcutaneous and pulmonary sarcoidosis in a patient with glaucoma. Clin Exp Dermatol. 2022 June 14; doi: 10.1111/ced.15290.

25. Levraut M, Martis N, Viau P, Suarez F, Queyrel V. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Ann Rheum Dis. 2019 Nov;78(11):1606–1607. doi: 10.1136/annrheumdis-2019-215387.

26. Wei JJ, Kallenbach LR, Kreider M, Leung TH, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019 Apr;5(4):360–361. doi: 10.1016/j.jdcr.2019.02.006.

27. Sejournet L, Kodjikian L, Grange L, Grumet P, Jamilloux Y, Seve P. Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis. Clin Exp Rheumatol. 2021 Feb;39(1):225–226. doi: https://doi.org/10.55563/clinexprheumatol/3gymd4.

28. Scheinberg M, Maluf F, Wagner J. Steroid-resistant sarcoidosis treated with baricitinib. Ann Rheum Dis. 2020 Sept;79(9):1259–1260. doi: 10.1136/annrheumdis-2020-217271.

29. Kerkemeyer KL, Meah N, Sinclair RD. Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series. J Am Acad Dermatol. 2021 Feb;84(2):581–583. doi: 10.1016/j.jaad.2020.10.016.

30. Talty R, Damsky W, King B. Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis. JAAD Case Rep. 2021 Oct;16:62–64. doi: 10.1016/j.jdcr.2021.08.012.

31. Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatol. 2020 Feb;2(2):106–109. doi: 10.1002/acr2.11112.

32. Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. N Engl J Med. 2018 Dec 27;379(26):2540–2546. doi: 10.1056/NEJMoa1805958.

33. Friedman MA, Le B, Stevens J, et al. Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study. Lung. 2021 Apr;199(2):147–153. doi: 10.1007/s00408-021-00436-8.

34. Collaborative group: MI(6) study group. Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib. Eur J Intern Med. 2022 Apr;98:119–121. doi: 10.1016/j.ejim.2021.12.016.

35. Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020 Mar;82(3):612–621. doi: 10.1016/j.jaad.2019.05.098.

36. Demir M, Kouranos V, Stoenchev K, et al. JAK-inhibitor Tofacitinib in Severe Laryngeal Sarcoidosis: A Case Report. Laryngoscope [Internet]. 2024;((Demir M., meryem.durgay@gmail.com; Kouranos V.; Stoenchev K.; Durham S.R.; Scadding G.W.; Saleh H.) Royal Brompton Hospital London, Guy’s, and St Thomas’ NHS Foundation Trust, London, United Kingdom). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2031430103&from=export doi: 10.1002/lary.31778.

37. Safadi M, Whittington K, Zahner S, Rubinstein I, Tsoukas M, Sweiss N. Recalcitrant cutaneous sarcoidosis treated with upadacitinib: Case report. JAAD Case Rep. 2024;51((Safadi M.) Internal Medicine Department, University of Illinois College of Medicine, Chicago, Illinois, United States):7–9. doi: 10.1016/j.jdcr.2024.06.019.

38. Farinha I, Ferreira PG. Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2024;41(2). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2033427048&from=export doi: 10.36141/svdld.v41i2.15655.

39. Russo G, Laffitte E. Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib. Acta Derm-Venereol [Internet]. 2024;104((Russo G., Giuseppe.russo@hcuge.ch; Laffitte E.) Department of Dermatology, University Hospital of Geneva, Geneva, Switzerland). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2028898542&from=export doi: 10.2340/actadv.v104.39970.

40. Yang Y, Yan J, Yang J, Wang P, Liu Y, Wang X. Janus kinase inhibitor Abrocitinib as an Off-Label treatment for tattoo granuloma with uveitis (TAGU). Australas J Dermatol. 2024;65(3):297–299. doi: 10.1111/ajd.14248.

41. Ianhez M, Miot HA, Caetano LVN, De Paula HM, Freire GGS, Torres PPTS. Sarcoidosis and Polymethyl Methacrylate (PMMA) Granulomas following COVID-19 Vaccination (ChAdOx1): Successful Treatment with Tofacitinib. Indian J Dermatol. 2024;69(4):328–332. doi: 10.4103/ijd.ijd_56_24.

42. Hindré R, Besnard V, Kort F, Nunes H, Valeyre D, Jeny F. Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis. Pulmonology. 2024;30(6):639–641. doi: 10.1016/j.pulmoe.2024.03.002.

43. Leffers HCB, Baslund B, Lindhardsen J, Krintel SB, Graudal N. Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response. Clin Exp Rheumatol. 2024;42(11):2167–2174. doi: 10.55563/clinexprheumatol/mmzdlj.

44. Jamilloux Y, Maucort-Boulch D, Kerever S, et al. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J. 2016 Dec;48(6):1700–1709. doi: 10.1183/13993003.00457-2016.

45. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011 June 1;183(11):1524–1530. doi: 10.1164/rccm.201010-1679OC.

46. Gerke AK, Judson MA, Cozier YC, Culver DA, Koth LL. Disease Burden and Variability in Sarcoidosis. Ann Am Thorac Soc. 2017 Dec;14(Suppl 6):S421–S428. doi: 10.1513/AnnalsATS.201707-564OT.

47. Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013 Sept;144(3):805–812. doi: 10.1378/chest.12-1728.

48. Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019 Dec;5(1):45. doi: 10.1038/s41572-019-0096-x.

49. Li H, Zhao X, Wang J, Zong M, Yang H. Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis. Gene. 2017 Jan;596:98–104. doi: 10.1016/j.gene.2016.09.037.

50. Zhou T, Zhang W, Sweiss NJ, et al. Peripheral Blood Gene Expression as a Novel Genomic Biomarker in Complicated Sarcoidosis. Morty RE, editor. PLoS ONE. 2012 Sept 12;7(9):e44818. doi: 10.1371/journal.pone.0044818.

51. Fritz D, Ferwerda B, Brouwer MC, van de Beek D. Whole genome sequencing identifies variants associated with sarcoidosis in a family with a high prevalence of sarcoidosis. Clin Rheumatol. 2021 Sept;40(9):3735–3743. doi: 10.1007/s10067-021-05684-w.

52. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000 Mar;17(1):60–66. PMID: 10746262.

53. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995 Apr 24;155(8):846–851. PMID: 7717793.

54. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990 Sept;23(3 Pt 1):487–489. doi: 10.1016/0190-9622(90)70246-e.

55. Bert A, El Jammal T, Kodjikian L, Gerfaud-Valentin M, Jamilloux Y, Seve P. Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis. Ocul Immunol Inflamm. 2023 Feb 7;1–7. doi: 10.1080/09273948.2023.2165952.

56. Rezaee M, Zangiabadian M, Soheili A, et al. Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis. Eur J Intern Med. 2023 Mar;109:42–49. doi: 10.1016/j.ejim.2022.12.003.

57. Adler BL, Wang CJ, Bui TL, Schilperoort HM, Armstrong AW. Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. Semin Arthritis Rheum. 2019 June;48(6):1093–1104. doi: 10.1016/j.semarthrit.2018.10.005.

58. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respiratory Medicine. 2006 Nov;100(11):2053–2059. doi: 10.1016/j.rmed.2006.02.017.

59. Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. Semin Arthritis Rheum. 2017 Oct;47(2):288–294. doi: 10.1016/j.semarthrit.2017.03.005.

60. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013 Feb 9;381(9865):451–460. doi: 10.1016/S0140-6736(12)61424-X.

61. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495–507. doi: 10.1056/NEJMoa1109071.

62. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):508–519. doi: 10.1056/NEJMoa1112072.

63. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 July 29;390(10093):457–468. doi: 10.1016/S0140-6736(17)31618-5.

64. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 July;73(7):924–939. doi: 10.1002/acr.24596.

65. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3–18. doi: 10.1136/ard-2022-223356.

66. van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214):2108–2117. doi: 10.1016/S0140-6736(19)32534-6.

67. Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Aug;80(8):1004–1013. doi: 10.1136/annrheumdis-2020-219601.

68. McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1;384(13):1227–1239. doi: 10.1056/NEJMoa2022516.

69. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19–34. doi: 10.1136/ard-2022-223296.

70. King B, Ohyama M, Kwon O, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687–1699. doi: 10.1056/NEJMoa2110343.

71. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. N Engl J Med. 2012 Aug 16;367(7):616–624. doi: 10.1056/NEJMoa1112168.

72. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 May 4;376(18):1723–1736. doi: 10.1056/NEJMoa1606910.

73. Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020 Nov;6(3):e001374. doi: 10.1136/rmdopen-2020-001374.

74. Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. 2019 July;71(7):1042–1055. doi: 10.1002/art.40841.

75. Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2022 Oct 5;annrheumdis-2022-222824. doi: 10.1136/ard-2022-222824.

76. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316–326. doi: 10.1056/NEJMoa2109927.

77. Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023 Jan;82(1):119–129. doi: 10.1136/ard-2022-222259.

78. Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2022 Sept 23;ard-2022-223050. doi: 10.1136/ard-2022-223050.

79. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019 Dec;21(1):89. doi: 10.1186/s13075-019-1866-2.

80. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology. 2019 Feb 1;58(Supplement_1):i34–i42. doi: 10.1093/rheumatology/key287.

81. Paolino A, Galloway J, Birring S, et al. Clinical phenotypes and therapeutic responses in cutaneous-predominant sarcoidosis: 6-year experience in a tertiary referral service. Clin Exp Dermatol. 2021 Aug;46(6):1038–1045. doi: 10.1111/ced.14614.

82. Álvarez-Reguera C, Prieto-Peña D, Herrero-Morant A, et al. Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review. Ther Adv Musculoskelet Dis. 2022;14:1759720X221093211. doi: 10.1177/1759720X221093211.

83. Zhang S, Cai Z, Mo X, Zeng H. Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients. Pediatr Rheumatol Online J. 2021 Nov 15;19(1):160. doi: 10.1186/s12969-021-00634-x.

84. Singh K, Wang A, Heald P, et al. Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. JAAD Case Rep. 2021 Jan;7:122–124. doi: 10.1016/j.jdcr.2020.11.016.

85. Alam M, Fang V, Rosenbach M. Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil. JAAD Case Rep. 2021 Mar;9:1–3. doi: 10.1016/j.jdcr.2020.12.021.

86. Sauvageau AP, Oulee A, Huang YY, Patel RM, Hamp L. Cutaneous sarcoidosis mimicking pigmented purpuric dermatosis. J Cutan Pathol. 2022 Sept 21;cup.14326. doi: 10.1111/cup.14326.

87. Costanza MB, Reynolds KA, Mervak JE. Management of treatment-resistant angiolupoid sarcoidosis with adalimumab and tofacitinib 2% ointment. JAAD Case Rep. 2023;38((Costanza M.B.) University of Michigan Medical School, Ann Arbor, MI, United States):61–63. doi: 10.1016/j.jdcr.2023.06.006.

88. Smith JS, Woodbury MJ, Merola JF. Ruxolitinib cream for the treatment of cutaneous sarcoidosis. JAAD Case Rep. 2023;38((Smith J.S.; Woodbury M.J.; Merola J.F., jfmerola@bwh.harvard.edu) Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts, United States):111–112. doi: 10.1016/j.jdcr.2023.05.032.